This is a routine insider sale to cover tax obligations from equity vesting, not a discretionary portfolio reduction. Monitor for any subsequent Form 4 filings to confirm the sale was executed as planned, but no material impact on the stock is expected.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $2.44entry
- T+1 · 11d ago −2.05%α −2.37% · $2.39
- T+5 · 5d ago −1.85%α −5.14% · $2.39
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Martin Wilson, an officer of Rocket Pharmaceuticals, filed a Form 144 notice to sell 53,389 shares of common stock, valued at approximately $127,808 based on the filing date price. The shares were acquired via restricted stock vesting on November 4, 2026, and the sale appears to be a routine transaction to cover tax obligations from equity award settlement, as indicated by similar prior sales.
Key Facts
- Officer Martin Wilson filed Form 144 to sell 53,389 shares of common stock.
- Estimated aggregate market value of the sale is $127,807.93.
- Shares were acquired via restricted stock vesting on November 4, 2026.
- The sale is intended to be executed through Fidelity Brokerage Services LLC.
- Prior sales by Wilson in August and September 2026 were for tax withholding purposes.
- The proposed sale date is November 5, 2026.
Financial Impact
Sale of 53,389 shares valued at ~$128K, representing approximately 0.05% of the company's $276M market cap.
Risk Factors
- Insider selling for tax purposes is standard and not indicative of negative sentiment.
- No additional context on the company's financial health or upcoming catalysts is provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007789 |
| Document: 0001959173-26-007789-index.html | 0001959173-26-007789 |
| Document: 0001959173-26-007789.txt | 0001959173-26-007789 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Viewing Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers